CTSA INFRASTRUCTURE FOR AIDS RESEARCH

CTSA 艾滋病研究基础设施

• 批准号: 8364993
• 负责人: Hugh A Sampson
• 金额: $ 18.97万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8364993
• 关键词: Acquired Immunodeficiency Syndrome; Clinical Sciences; Institutes; Research; Research Infrastructure; Translational Research

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. Despite great scientific advances over the past decade, the translation of these discoveries to the benefit of patients has been hampered by a number of traditional barriers. The overall goal of the Mount Sinai institutes of Clinical & Translational Sciences is to establish a new research paradigm at Mount Sinai, which will create an integrated multidisciplinary environment that will enable translation of cutting-edge research more quickly and easily from "bench-to-bedside-to-implementation" in the community; train and create an "academic home" for the clinical and translational investigators of tomorrow; and supply the governance, facilities, resources and opportunities needed to elevate the clinical research enterprise so that clinical investigators can take full advantage of Mount Sinai's Translational Research Institutes and potential collaborators in Mount Sinai Hospital and its affiliates, the School of Medicine and partnering institutions, and other CTSA programs around the country. This transformation will be achieved by fulfilling the following Specific Aims: (1) redesign the institutional research enterprise infrastructure and governance by integrating research functions across administrative, departmental and intellectual boundaries, enhancing and promoting interactions between basic scientists and clinical investigators, and streamlining administrative procedures to facilitate the start-up of clinical trials and the dissemination of results; (2) establish a Translational Discoveries Program to facilitate and expedite clinical research by providing consultation, oversight and facilities for clinical and translational research, engaging the surrounding community and our affiliates to rapidly translate health benefits to the general population, and developing new methodologies to improve clinical trial design and reduce participant burden; (3) train and support the translational investigators of tomorrow by overseeing a multi-disciplinary, doctoral degree-granting program in clinical and translational research for all health care professionals, developing a program to recruit, enhance career development and retain clinical and translational researchers, providing an academic home where new collaborations can be formulated; (4) establish an Experimental Therapeutics& Technologies Program to stimulate the development of new methodologies in clinical and translational research by developing an institution-wide mentored program to identify and develop novel clinical and translational research projects; and (5) establish an institution-wide biomedical information infrastructure that can connect basic researchers, clinical researchers, caregivers and laboratories with an integrated network of information. RELEVANCE (See instructions): The establishment ofthe Mount Sinai Institutes of Clinical & Translational Sciences would create an effective, efficient and centralized research administrative structure, foster and reward interdisciplinary collaborations, educate and retain the clinical and translational investigators of the future, enable translation of basic scientific discoveries into clinical practice, and deliver to our diverse community new therapies and a standard of care that would have been unimaginable even five years ago.

该子项目代表了 CTSA 资金百分比的估计 被用于广泛的研究领域（艾滋病研究、儿科研究或 临床试验）。 列出的总成本只是 CTSA 金额的估计值 该研究领域的基础设施，而不是直接资助 NCRR 向子项目或子项目工作人员提供的补助金。 尽管过去十年科学取得了巨大进步，但将这些发现转化为造福患者的过程仍受到许多传统障碍的阻碍。西奈山临床与转化科学研究所的总体目标是在西奈山建立一个新的研究范式，这将创建一个综合的多学科环境，使尖端研究能够更快、更轻松地从“实验室到社区中的“从床边到实施”；为未来的临床和转化研究人员培训和创建一个“学术之家”；提供提升临床研究事业所需的治理、设施、资源和机会，以便临床研究人员能够充分利用西奈山的转化研究所以及西奈山医院及其附属机构、医学院和合作机构的潜在合作者，以及全国各地的其他 CTSA 计划。这一转变将通过实现以下具体目标来实现：（1）重新设计机构研究企业基础设施和治理，整合跨行政、部门和知识边界的研究职能，加强和促进基础科学家和临床研究人员之间的互动，并简化行政程序促进临床试验的启动和结果的传播； (2) 建立转化发现计划，通过为临床和转化研究提供咨询、监督和设施，让周围社区和我们的附属机构参与，将健康益处迅速转化为普通人群，并开发新的方法来改善临床研究，从而促进和加速临床研究。临床试验设计并减轻参与者负担； (3) 通过监督所有医疗保健专业人员的临床和转化研究多学科、博士学位授予计划，制定招募、促进职业发展和留住临床和转化研究人员的计划，培训和支持未来的转化研究人员，提供一个可以制定新合作的学术家园； (4) 建立实验治疗与技术计划，通过开发机构范围的指导计划来识别和开发新的临床和转化研究项目，从而刺激临床和转化研究新方法的发展； （5）建立全机构范围的生物医学信息基础设施，通过综合信息网络连接基础研究人员、临床研究人员、护理人员和实验室。相关性（参见说明）：西奈山临床与转化科学研究所的建立将创建一个有效、高效和集中的研究管理结构，促进和奖励跨学科合作，教育和留住未来的临床和转化研究人员，使将基本科学发现转化为临床实践，并为我们多元化的社区提供新的疗法和护理标准，这在五年前也是难以想象的。